India, Sept. 7 -- Matinas BioPharma Holdings, Inc. (MTNB), a biopharmaceutical company, announced that it has received a notice from NYSE American indicating that it is not in compliance with continued listing standards requiring stockholders' equity of at least $2.0 million for companies that have reported losses in two of their three most recent fiscal years
Notably, as of June 30, 2026, the company had stockholders' equity of $1.8 million and has had losses from continuing operations and/or net losses in its five most recent fiscal years ended December 31, 2025.
The company was already non-compliant with Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide.
On May 4, 2026, the company submitted a plan to the NYSE A...